[AFL] Aflac: Q3 2026 Earnings Test Japan Benefit Ratio After Annual Review

Aflac (AFL) is an insurance group built on cancer and medical insurance in Japan and workplace supplemental insurance in the United States, and the Drillr earnings calendar shows it reporting results for the Third quarter 2026 (three months ended September 30, 2026) on 2026-11-05[1]. In the latest disclosed period, the second quarter of 2026, total revenues were $4.1 billion, net earnings were $825 million ($1.63 per diluted share), adjusted earnings fell 7.7% to $883 million and adjusted EPS fell 1.7% to $1.75; the Japan segment ran a 64.0% benefit ratio and a 34.3% pretax margin, while the U.S. segment ran a 49.5% benefit ratio and a 20.9% pretax margin[2]. After the quarter, management moved its full-year Japan benefit ratio outlook, which excludes the third-quarter actuarial assumption review, to the high end of its 60% to 63% range, and cut its 2026 U.S. net earned premium growth outlook to just below the 3% to 6% range[2]. Ten analysts compiled by Drillr put consensus third-quarter adjusted EPS at $1.80 (range $1.71 to $1.93), and three analysts put consensus revenue at $4.119 billion[3].

Three things matter most in Aflac's Q3 2026 earnings, starting with the Japan benefit ratio. The first is the Japan annual review: the company updates its actuarial assumptions every third quarter, and in 2025 that update cut Japan benefits by about ¥68 billion[4], so the reported ratio this quarter will be pulled down by a one-time release, and the figure that matters is whether the underlying ratio excluding the review stays at or below 63%, against 64.0% already in the second quarter[2]. The second is whether new sales in Japan can offset paid-up policies and lapses: first-half Japan sales rose 7.0% to ¥37.3 billion, yet underlying earned premiums still fell 1.4% in the second quarter and persistency slipped to 92.7%[2]. The third is growth versus claims in the U.S. group business: U.S. net earned premiums grew only 2.3% in the second quarter while the benefit ratio rose 220 basis points to 49.5% on group disability claims[2], and third-quarter data should help show whether that was a short-term swing or a lasting rise driven by product mix.

Company Background and Business Structure

Aflac is an insurance group headquartered in the United States that earns most of its profit in Japan. The company is based in Columbus, Georgia, trades on the New York Stock Exchange, and is led by Chairman and CEO Daniel P. Amos[2]. It pioneered the Japanese cancer insurance market in 1974, remains the number one provider of cancer insurance in Japan, and is the largest insurer in Japan by cancer and medical policies in force, the so-called third sector products[4]. At June 30, 2026, Aflac Japan accounted for 75% of the company's total assets and, in the second quarter, 51% of total adjusted revenues[5].

Aflac reports two insurance segments, Aflac Japan and Aflac U.S., plus Corporate and other, and Japan is the larger segment. In 2025, Aflac Japan generated total adjusted revenues of $9.357 billion, including net earned premiums of $6.744 billion (¥1,009 billion) and adjusted net investment income of $2.581 billion, and pretax adjusted earnings of $3.440 billion (¥514 billion)[4]. Its products are mainly cancer and medical insurance that pay fixed lump-sum or daily benefits on diagnosis or hospitalization, helping customers cover costs that Japan's national health insurance does not reimburse; cancer accounted for 67.2% of 2025 new sales, and at year-end the company had more than 22 million individual policies in force, about 14 million of them cancer policies[4]. Aflac Japan also sells Tsumitasu savings-type life insurance and other first sector products such as WAYS[2], and management says first sector business makes up less than 20% of Japan's in-force business[6].

The Japan business relies on a highly diversified distribution network. At the end of 2025, it sold through about 6,300 sales agencies (with about 112,000 licensed sales associates), about 20,000 Japan Post outlets, about 37,000 Dai-ichi Life representatives, about 3,700 Daido Life representatives, and agreements with about 90% of Japan's banks[4]. The Dai-ichi Life alliance began in 2001, the Japan Post Group alliance began in 2008 and was strengthened in 2013, and the Daido Life alliance began in 2013[4].

The U.S. segment is the group's second business line and sells supplemental insurance through the workplace. In 2025, Aflac U.S. generated total adjusted revenues of $6.903 billion, net earned premiums of $5.999 billion and pretax adjusted earnings of $1.421 billion, with annualized premiums in force of $6.7 billion at year-end, up 4.9%[4]. It sells accident, disability, critical care, hospital indemnity, dental and vision, and life coverage to employees through employers, and in 2025 new sales were 26.4% disability, 19.8% critical care, 18.9% accident and 15.5% life[4]. Corporate and other mainly reflects investment income on parent-company cash and liquid assets, interest expense, and runoff from closed blocks of business[7], and Aflac Japan also has an internal cancer reinsurance arrangement with the group's own reinsurer, Aflac Re[4].

Financial History and Current Position

The 2025 fiscal year shows stable earnings and heavy capital return. In 2025, Aflac reported adjusted earnings of $4.008 billion, adjusted EPS of $7.49 and net earnings of $6.82 per diluted share[4]. It repurchased $3.530 billion of stock and paid cash dividends of $2.32 per share, up 16.0%, and in November 2025 the board announced a 5.2% increase in the quarterly dividend effective with the first quarter of 2026[4].

The two segments moved in different directions in 2025: Japan shrank while the U.S. grew modestly. Aflac Japan's 2025 net earned premiums fell 3.9% to ¥1,009 billion, adjusted net investment income fell 5.9% to ¥386 billion, and pretax adjusted earnings fell 2.7% to ¥514 billion, for a 36.7% margin and a 59.3% benefit ratio[4]. Aflac U.S. net earned premiums rose 2.9% to $5.999 billion, pretax adjusted earnings were essentially flat at $1.421 billion, the margin was 20.6% and the benefit ratio was 47.3%[4].

The first quarter of 2026 was still solid. First-quarter total revenues were $4.3 billion, net earnings were $1.0 billion ($1.98 per diluted share), and adjusted EPS rose 5.4% to $1.75[8]. Japan pretax adjusted earnings rose 8.3% to ¥119.1 billion for a 35.0% margin, while U.S. pretax adjusted earnings were $363 million for a 20.4% margin[8].

Adjusted earnings fell in the second quarter of 2026, mainly because of currency translation. Second-quarter total revenues fell 1.0% to $4.1 billion, and net earnings of $825 million ($1.63 per diluted share) included $153 million of net investment losses[2]. Adjusted earnings fell 7.7% to $883 million and adjusted EPS fell 1.7% to $1.75, but excluding currency effects adjusted EPS rose 1.1% to $1.80; first-half adjusted EPS was $3.50[2]. Japan pretax adjusted earnings rose 3.4% to ¥118.2 billion in the quarter, while U.S. pretax adjusted earnings fell 4.6% to $370 million[2].

Capital return and liquidity remained ample at the end of the second quarter. Aflac repurchased $983 million of stock and paid $309 million of dividends in the second quarter, and cash spent on buybacks in the first half was $1.984 billion[2][5]; at June 30, shareholders' equity was $30.3 billion and adjusted book value was $55.01 per share[2]. The parent held $3.3 billion of unencumbered liquidity, $2.3 billion above its $1 billion minimum, and adjusted leverage was 21.8%, inside the 20% to 25% target range[6].

Operating Model

Japan revenue depends on a slow runoff of in-force premiums and on new sales that partly replace it. Net earned premiums come from premiums in force: Japan's annualized premiums in force were ¥1.18 trillion at the end of 2025, down 2.5%, mainly because limited-pay policies reached paid-up status, and each year the in-force base adds new sales (¥74.4 billion in 2025) and loses lapses (persistency of 93.1%) and paid-up policies[4]. By June 30, 2026, annualized premiums in force had fallen further to ¥1.16 trillion, down 2.7%[5]. The lag in this chain is long, because new sales take years of accumulated premiums to show up in earned premiums; on the first-quarter call, management said flat in-force premiums would require roughly ¥90 billion of sales a year[7].

Japan investment income has a yen-asset component and a dollar-asset component, less hedge costs. In 2025, dollar-denominated investment income was ¥259 billion and yen-denominated income was ¥134 billion, and after ¥7 billion of hedge costs adjusted net investment income was ¥386 billion; Aflac Japan's dollar-denominated investments had an amortized cost of about $25.1 billion[4]. When the yen weakens, translating dollar income into yen magnifies yen-basis growth, but Japan results reported in dollars and group EPS are pushed down[4][8].

U.S. revenue is roughly net earned premiums plus adjusted net investment income and is driven mainly by new sales and persistency. In 2025, U.S. net earned premiums were $5.999 billion and adjusted net investment income was $830 million, with $6.7 billion of annualized premiums in force at year-end and 79.2% persistency[4]. At March 31, 2026, U.S. annualized premiums in force had grown 4.6% to $6.8 billion[9], and new sales and persistency turn into earned premiums through the in-force base over the following quarters.

Segment pretax adjusted earnings equal net earned premiums less benefits, plus investment and other income, minus commissions, amortization of deferred acquisition costs and operating expenses. Japan's 2025 benefit ratio was 59.3%, its expense ratio 20.5% and its pretax margin 36.7%, compared with 64.0%, 20.2% and 34.3% in the second quarter of 2026[4][2]. The same three U.S. figures were 47.3%, 38.3% and 20.6% in 2025 and 49.5%, 36.1% and 20.9% in the second quarter[4][2]. Benefits include reserve remeasurement: the actuarial assumption update each third quarter changes reserves in one step, and in 2025 it produced gains of about ¥68 billion in Japan and $60 million in the U.S.[4], which lowered the benefit ratio directly in that quarter.

Adjusted EPS and parent-company cash both come from segment earnings, but along different paths. Segment earnings plus the Corporate and other result (a $10 million pretax loss in the second quarter[6]), less income taxes, divided by diluted shares give adjusted EPS; investment gains and losses and expected credit losses go into GAAP net earnings but not adjusted earnings[2][5]. Premiums arrive before claims are paid, so the resulting funds sit in the insurance subsidiaries' investment portfolios, and parent-company cash comes mainly from subsidiary dividends; Japan's economic solvency ratio fell to 226% in the second quarter mainly because of large subsidiary dividends[2]. Aflac also changed its internal reinsurance limit for Japan from 10% of U.S. GAAP assets to 30% of FSA reserves to reduce risk and improve balance sheet efficiency[2].

Industry and Competitive Position

Aflac's advantage in Japan rests on scale, brand and distribution. After Japan's insurance market was deregulated in 2001, more companies began offering stand-alone cancer and medical insurance and competition intensified, but the company believes its premiums in force, well-known brand, low-cost operations and broad distribution will keep it a leading provider of third sector products[4]. Its long-running alliances with Dai-ichi Life, Japan Post and Daido Life, together with agreements covering about 90% of Japan's banks, form the core of that network[4].

Competition in U.S. supplemental insurance shows up mainly as product and channel expansion. Aflac has expanded in group voluntary benefits, group life and disability, and network dental and vision, and in the second quarter group product sales rose 7.1% and network dental and vision sales rose 47%[8][6]. That growth also brings claims pressure: the 10-Q attributes the rise in the U.S. benefit ratio to higher incurred claims on certain group products tied to premium growth[5].

Capital strength is another advantage. At the end of 2025, Aflac Japan's solvency margin ratio (SMR) was 995% and the Aflac U.S. combined risk-based capital (RBC) ratio was 570%; the company targets an economic solvency ratio (ESR) of 170% to 230% for Japan and a combined RBC range of 350% to 450% for the U.S.[4]. At June 30, 2026, Japan's ESR was estimated at 226% and U.S. combined RBC at slightly above 600%[2].

The peer comparison the available material supports has clear limits. The material contains only the company's own description of its competitive position, with no comparable benefit ratios or market shares for Japanese or U.S. peers, so it cannot show how large Aflac's profitability edge over competitors is.

Core Debates

After the annual review, can Japan keep its benefit ratio under 63%?

The Japan benefit ratio is the largest single variable in group earnings. On 2025 figures, Aflac Japan's $3.440 billion of pretax adjusted earnings was about 70% of the two insurance segments' combined total, and benefits are the segment's largest cost[4]. The third-quarter 2025 assumption update cut Japan benefits by about ¥68 billion and lowered the full-year benefit ratio to 59.3%; without it, the full-year ratio would have been about 66%[4]. The 2026 guidance of 60% to 63% excludes the review while the reported third-quarter figure includes it, so readers need to separate the one-time release from underlying benefits[2].

Second-quarter evidence shows the underlying ratio already sitting near the top of guidance. Japan's second-quarter benefit ratio was 64.0%, down 250 basis points from a year earlier, and the first-half ratio was 63.4%, which led management to move its full-year outlook to the high end of the range[2]. The 10-Q attributes the year-over-year decline to the third-quarter 2025 assumption updates and higher reserve remeasurement gains[5]; management says cancer and hospitalization trends remain favorable, but second-quarter remeasurement gains came in about 60 basis points below plan because the lapse mix shifted toward newer, lower-reserve policies, which releases less reserve on lapse[2][6]. One reading is that underlying claims are still improving and only lapse releases have dipped for now; the other is that the 2025 review already booked most of the favorable trend at once, and the underlying ratio will drift back above 64%.

The debate has three numeric baselines, and it reaches EPS through reserves. The Japan benefit ratio excluding the review was 64.0% in the second quarter and 63.4% in the first half; reserve remeasurement gains from the review were about ¥50 billion in the third quarter of 2024 and about ¥68 billion in the third quarter of 2025; and the Japan pretax margin was 34.3% (¥118.2 billion) in the second quarter, 34.6% (¥237.3 billion) in the first half and 36.7% for full-year 2025[4][2]. The transmission runs from cancer and hospitalization claims trends and the lapse mix created by new products, to the third-quarter morbidity and lapse assumption updates, to reserve remeasurement gains, and then to the Japan benefit ratio, pretax adjusted earnings and group adjusted EPS.

The third-quarter report can test these baselines, but readers have to strip out the review themselves. The questions are whether the review release lands between about ¥50 billion and ¥68 billion, whether the benefit ratio excluding the review is at or below 63% and at least no higher than the second quarter's 64.0%, and whether the pretax margin excluding the review stays inside the 33% to 36% guidance range[2]. A review gain below ¥50 billion would mean the favorable room in long-term claims assumptions is narrowing, and an ex-review ratio above 64.0% would undo the claim that the full year sits at the high end of guidance. Aflac does not disclose a quarterly underlying ratio before the review, so the figure can only be derived from the reported ratio and the disclosed review amount.

Can new sales in Japan keep up with policies that stop paying premiums?

Japan premiums are the backbone of group revenue, but they have shrunk for several years. In 2025, Japan net earned premiums of $6.744 billion were about 40% of the two insurance segments' total adjusted revenues and fell 3.9% in yen, partly because of the internal cancer reinsurance with Aflac Re (about ¥21 billion) and limited-pay policies reaching paid-up status (about ¥15 billion)[4]. Japan net earned premiums fell another 3.8% in the first half of 2026, which also brought a new external reinsurance transaction for WAYS and Tsumitasu[2]. For premiums to stop falling, new sales have to keep growing, and new products cannot simply move existing customers into a new policy.

Sales growth this year is real, but it has arrived alongside falling persistency. Japan sales rose 25.5% to ¥17.7 billion in the first quarter, then fell 5.6% to ¥19.6 billion in the second quarter against a high base set by the March 2025 launch of Miraito cancer insurance, for a first-half total of ¥37.3 billion, up 7.0%[8][2]. The growth came from Anshin Palette medical insurance, Miraito cancer insurance and Tsumitasu savings life insurance, and management says Tsumitasu helps reach younger customers and drives cross-sales of cancer and medical products[6]. Persistency fell from 93.7% a year earlier to 92.7%, which the company attributes to lapse and reissue activity on new products[2]; the other reading is that new products are mainly replacing existing policies and lapses are offsetting sales growth, which is why underlying earned premiums still fell 1.4% in the second quarter, and if so, persistency will not recover in the second half.

The baseline for this debate has three parts: sales, persistency and underlying earned premiums. Japan new sales were ¥74.4 billion for full-year 2025 and ¥37.3 billion in the first half of 2026, which puts second-half 2025 sales at about ¥39.5 billion when the full year is reduced by the back-calculated first half[4][2]. Persistency was 93.1% at the end of 2025 and 92.7% at June 30, 2026, and underlying earned premiums (excluding reinsurance, paid-up policies and the deferred profit liability) fell 1.3% in the first quarter and 1.4% in the second[4][7][2]. The transmission runs from new products and promotion through agencies, post offices and banks, to applications and new annualized premium sales, then, after lapses and reissues, paid-up policies and external reinsurance cessions, to annualized premiums in force and finally Japan net earned premiums.

Management's full-year targets set a testable bar for the third quarter. Management still looks for 2026 Japan sales to exceed 2025 and says the ¥80 billion full-year target remains possible[6]; with ¥37.3 billion booked in the first half, the second half needs at least about ¥37.1 billion to beat last year, a decline of no more than about 6.2% from the second half of 2025, while ¥80 billion would need about ¥42.7 billion, or growth of about 8%. The third quarter should therefore show whether sales decline less than 6.2% year over year, ideally growing more than 8%, whether persistency holds at 92.7%, and whether the decline in underlying earned premiums stays within 1.4%. If new sales growth comes mainly from existing customers switching policies, if the decline in underlying earned premiums widens, or if third-quarter sales fall more than 6.2%, the goal of beating 2025 will come under pressure.

Will claims eat into the growth of the U.S. group business?

The U.S. segment drives the other half of group revenue growth, but its growing products carry higher claims. In 2025, Aflac U.S. total adjusted revenues of $6.903 billion were about 40% of the two insurance segments' combined total, and recent growth has come mainly from group voluntary benefits, group life and disability, and network dental and vision[4][8]. The 10-Q attributes the rise in the benefit ratio to higher incurred claims on certain group products tied to premium growth, which means faster group growth also means more claims pressure[5]. In the second quarter premium growth slowed to 2.3%, the benefit ratio rose to 49.5%, and management cut its full-year premium growth outlook to just below the 3% to 6% range[2].

Second-quarter data showed both group sales momentum and rising claims. First-half U.S. net earned premiums were about $3.1 billion, up 2.9%, and sales were $667 million, up 2.8%, with group product sales up 7.1% and network dental and vision sales up 47% in the second quarter[2][6]. The second-quarter benefit ratio was 49.5%, up 220 basis points, which the company attributed to higher incurred group disability claims relative to favorable prior-year results; the expense ratio was 36.1% and the pretax margin of 20.9% remained above the 17% to 20% full-year guidance[2]. One reading is that second-quarter disability claims were a short-term swing, and on the first-quarter call management said the underlying benefit ratio was right at 48% while warning that the ratio can be volatile from quarter to quarter[7]; the other is that the group share keeps rising, the benefit ratio will gradually move above 50%, and the margin will fall back inside the guidance range.

The baseline for this debate comes from premium growth, sales and the benefit ratio. U.S. net earned premium growth was 2.9% for full-year 2025 ($5.999 billion), 2.9% in the first half of 2026 and 2.3% in the second quarter; new sales were $349 million in the second quarter, up 2.6%, and $667 million in the first half, up 2.8%; and the benefit ratio excluding the review was 47.3% for full-year 2025, 47.2% in the first quarter of 2026 and 49.5% in the second[4][2][7]. The transmission runs from group sales through the employer channel to new sales and persistency, which set U.S. net earned premiums, while the rising group share and disability claim incidence set the benefit ratio and, in the end, U.S. pretax adjusted earnings.

The third quarter can test whether disability claims were a one-off swing. The questions are whether net earned premium growth is at least 2.3%, whether the benefit ratio returns below 49.5% as group disability claims ease, and whether sales keep growing ahead of what management describes as a seasonally strong fourth quarter[6]. A benefit ratio that stays above 49.5% while the margin falls back into the 17% to 20% range would strengthen the case for rising group claims, and premium growth below 2.3% would make management's 3% to 6% net earned premium CAGR for 2025 to 2027 harder to reach[2].

After the bond swap, can Japan’s investment income stop falling?

Investment income is the second pillar of Japan earnings, and it fell in 2025. Insurers collect premiums before they pay claims and invest the money in between; Aflac Japan's adjusted net investment income fell 5.9% to ¥386 billion in 2025, mainly because of lower income from floating-rate dollar assets[4]. In the second quarter of 2026, the company repositioned about $4.8 billion, roughly 5% of the consolidated portfolio and mostly in Japan, through switch trades, and management says this should lift annualized run-rate investment income by more than $50 million[6]. The third quarter is the first full quarter after the repositioning.

Second-quarter investment income split between the two asset types. Japan adjusted net investment income fell 2.9% to ¥98.3 billion in the second quarter: dollar-denominated income rose 4.2% to ¥70 billion, partly because of the weaker yen, while yen-denominated income fell 14.9% to ¥30 billion, which the company attributed to lower call income and lower dollar floating-rate income[2]. In the first quarter, by contrast, it rose 4.0% to ¥92.8 billion, for a first-half total of ¥191.0 billion, up 0.4%[8][2]. One reading is that the second-quarter decline was mainly a quarterly swing in call income and income will recover after the repositioning; the other is that shrinking floating-rate assets and falling dollar rates are still pressing on income, and the $50 million lift will only partly offset that.

The baseline for this debate covers investment income and the exchange rate used to translate it. Japan adjusted net investment income was ¥92.8 billion (+4.0%) in the first quarter, ¥98.3 billion (−2.9%) in the second quarter and ¥191.0 billion (+0.4%) in the first half; dollar-denominated investment income was ¥70 billion (+4.2%) in the second quarter; and the average yen/dollar rate was 159.45 in the second quarter versus 144.60 a year earlier[8][2]. The transmission runs from U.S. and Japanese interest rates, call income and the size of floating-rate assets, to the repositioning and new money yields, to dollar and yen investment income, with dollar income translated into yen at average rates and hedge costs deducted to give Japan adjusted net investment income and, finally, Japan pretax earnings.

The third quarter needs to separate yield improvement from currency translation. The questions are whether Japan adjusted net investment income in yen turns to year-over-year growth, how much of any dollar-income growth comes from yield rather than yen translation, and whether the decline in yen-asset income narrows. If the fall in floating-rate income outweighs the lift from the repositioning, or if expected credit losses rise on commercial real estate and middle market loans, the case for improving investment income weakens; at the end of 2025, Aflac Japan's dollar portfolio held about $2.8 billion of transitional real estate loans and about $3.8 billion of middle market loans, all floating rate[4].

Risks and Falsifiers

Currency risk acts directly on earnings and book value reported in dollars. The average yen/dollar rate in the second quarter was 159.45, 9.3% weaker than a year earlier, which cut adjusted EPS by $0.05, and the first-half hit was $0.07; at June 30, shareholders' equity included a $5.0 billion unrealized foreign currency translation loss[2]. If the currency effect on third-quarter adjusted EPS is no worse than −$0.05 and adjusted EPS excluding currency keeps growing year over year, this risk has not worsened.

The Japan cybersecurity incident is a risk that has not yet been quantified. In June 2026, Aflac Japan found that an unauthorized third party had accessed some of its systems, the affected files contained policy and coverage details, personal information and bank account information, and the company notified Japan's Financial Services Agency and completed notification of affected individuals[5]. The company says the potential loss cannot be reasonably estimated and does not believe the incident is reasonably likely to have a material impact on its financial condition; if an impact appears, it could show up in the Japan expense ratio (20.2% in the second quarter) and in the pace of distribution activity[5][2]. If the third-quarter Japan expense ratio stays near the low end of the 20% to 23% guidance and the company discloses no material incident-related cost or regulatory penalty, the risk remains limited.

Claims-assumption risk points at the Japan benefit ratio and third-quarter earnings. If favorable cancer and hospitalization trends fade, or if the lapse mix on new products keeps reducing reserve releases, the underlying Japan benefit ratio will rise; on quarterly net earned premiums of about ¥245 billion, each 1 percentage point increase in the underlying ratio cuts quarterly pretax earnings by about ¥2.45 billion, and each ¥10 billion shortfall in the review gain cuts third-quarter pretax earnings by the same amount[2]. The falsifier is a third-quarter ratio excluding the review of no more than 63.0% together with a review gain of at least ¥50 billion.

In-force runoff risk points at Japan premium revenue. If paid-up policies, reinsurance cessions and lapses accelerate faster than new sales can offset, Japan premiums and the earnings they support will keep falling; on 2025 Japan net earned premiums of ¥1,009 billion, each additional 1 percentage point decline in underlying earned premiums removes about ¥10 billion of annual premium[4]. The falsifier is third-quarter persistency of at least 92.7% together with a decline in underlying earned premiums of no more than 1.4%.

Group claims risk points at the U.S. margin. If group disability claims stay above expectations, the shift in product mix would push the U.S. benefit ratio toward the top of its 48% to 52% guidance; on quarterly net earned premiums of about $1.5 billion, each 1 percentage point rise in the ratio cuts quarterly pretax earnings by about $15 million[2]. The falsifier is a third-quarter ratio excluding the review of no more than 49.5% together with a pretax margin of at least 20.6%.

Credit risk points at GAAP net earnings and investable income. The transitional real estate loans and middle market loans in Aflac Japan's dollar portfolio are floating-rate assets, so credit deterioration would raise expected credit losses and reduce investment income[4]; second-quarter net investment losses included $77 million of current expected credit losses, which count in GAAP net earnings but not adjusted earnings[2]. The falsifier is third-quarter expected credit losses no higher than the second quarter's $77 million, with no reported deterioration in the loan portfolio.

What to Watch Next

• Japan annual review and underlying benefits: the review release (about ¥68 billion in the third quarter of 2025 and about ¥50 billion in 2024) and the Japan ratio excluding it (64.0% in the second quarter, 63.4% in the first half). A release of at least ¥50 billion with an ex-review ratio at or below 63% supports guidance; an ex-review ratio above 64.0% undoes the high-end framing.
• Japan new sales versus paid-up runoff: sales (¥37.3 billion in the first half, +7.0%), persistency (92.7%) and underlying earned premiums (−1.4% in the second quarter). A sales decline smaller than 6.2% with persistency holding at 92.7% supports the path to stabilization; a decline larger than 6.2% or a wider premium decline strengthens the replacement-sales reading.
• U.S. group growth versus claims: net earned premium growth (+2.3%) and the benefit ratio (49.5%) in the second quarter. Growth of at least 2.3% with the ratio back below 49.5% supports the short-term-swing reading; a ratio that stays above 49.5% strengthens the rising-claims reading.
• Japan investment income: yen-basis adjusted net investment income (¥98.3 billion, −2.9% in the second quarter) in the first full quarter after the repositioning. A return to growth supports the repositioning; a further decline points to a heavier floating-rate drag.
• Currency and credit: the currency effect on EPS (−$0.05 in the second quarter) and expected credit losses ($77 million). An effect no worse than −$0.05 and credit losses no higher than $77 million mean neither risk has widened.

Conclusion

Two business lines drive Aflac's earnings. Japan cancer and medical insurance holds a pretax margin of 34% to 37% through a relatively low benefit ratio and investment income even as premiums slowly shrink, while U.S. workplace supplemental insurance relies on group products for premium growth of about 2% to 3% and a margin near 20%[4][2]. Capital is ample: cash spent on buybacks was $1.984 billion in the first half of 2026 and Japan's ESR stood at 226% at June 30[5][2]. The central unresolved relationships are whether Japan's benefit ratio excluding the review can hold at 63%, whether new sales can keep pace with paid-up policies and lapses, whether claims will offset U.S. group growth, and whether investment income stops falling after the repositioning.

Between the August 6, 2026 second-quarter release and October 31, the available material consisted mostly of earnings call summaries and transcripts and institutional holdings changes, and it contained no outside analysis offering an independent judgment on the Japan benefit ratio or the U.S. group business. For that reason no outside view is cited here, scattered aggregate opinions are not treated as market consensus, and any judgment on these debates rests only on the company's own disclosures.

The current understanding would be materially strengthened by a combination of results arriving together: a third-quarter review release of about ¥50 billion to ¥68 billion with a Japan ratio excluding the review at or below 63%, a Japan sales decline smaller than 6.2% with persistency holding at 92.7%, a U.S. benefit ratio back below 49.5% with premium growth of at least 2.3%, and yen-basis investment income returning to growth. Conversely, a review gain below ¥50 billion and an ex-review ratio above 64.0%, alongside a wider decline in underlying earned premiums and a still-rising U.S. benefit ratio, would call for a fresh look at both the resilience of Japan margins and the quality of U.S. growth.

Sources

[1] AFL earnings calendar updated 2026-10-30 · 2026-10-30 · Drillr earnings calendar

[2] AFL Q2 2026 8-K filed 2026-08-06 · 2026-08-06 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000004977&type=8-K

[3] Drillr analyst estimates AFL Q3 2026 retrieved 2026-10-30 · 2026-10-30 · Drillr analyst estimates · https://gateway.drillr.ai/mcp/private

[4] AFL 10-K filed 2026-02-25 · 2026-02-25 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000004977&type=10-K

[5] AFL Q2 2026 10-Q filed 2026-08-07 · 2026-08-07 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000004977&type=10-Q

[6] AFL Q2 2026 earnings call 2026-08-07 · 2026-08-07 · earnings-call · https://gateway.drillr.ai/mcp/private

[7] AFL Q1 2026 earnings call 2026-04-30 · 2026-04-30 · earnings-call · https://gateway.drillr.ai/mcp/private

[8] AFL Q1 2026 8-K filed 2026-04-29 · 2026-04-29 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000004977&type=8-K

[9] AFL Q1 2026 10-Q filed 2026-05-06 · 2026-05-06 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000004977&type=10-Q